Researchers unveil reliable new approach to cancer drug delivery

Prostate, breast and other cancer patients may be offered a new, stauncher targeted drug delivery system to treat their diseases in the next decade.
Using atomic force microscopy and computer simulations, researchers from Lawrence Livermore National Laboratory and the UC Davis Cancer Center have unveiled a new and reliable technique to characterize the binding interaction of multivalent molecules designed for targeted drug delivery in cancer treatment.

Image: Stretching and breaking multiple parallel antibody-antigen bonds with Atomic Force Microscopy (AFM). The model shows an AFM tip with three tethered single-chain antibody fragments that mimic the architecture of a cancer drug. Two of the antibody fragments bind the target cancer marker MUC1 on the surface. Researchers measure the interactions’ strength by pulling on the MUC1-antibody bonds with the cantilever. This technique can help to design more efficient immunotherapeutics for cancer treatment. Ed Lau/LLNL

The Livermore team used atomic force microscopy (AFM) to measure the binding forces between several single-chain antibody fragments and Mucin1 peptide. Mucin1 is commonly found in large quantities in a variety of epithelial cells in the human body, and one of its specific forms is a characteristic marker for prostate, breast, colon, lung, gastric and pancreatic cancers. Binding between Mucin1 and antibodies recognizing the marker is critical to targeted drug delivery for cancer patients.

“We found a very good way of quantifying the drug binding affinity, which determines the drug’s efficiency,” said Aleksandr Noy, a researcher in LLNL’s Chemical Biology and Nuclear Sciences Division (CBDN), who along with CBDN postdoctoral student Todd Sulchek is the lead author of a paper that appears in the Proceedings of the National Academy of Sciences online edition for the week of Oct. 31-Nov. 4. “Not only does this technique aid doctors in delivering targeted drugs in cancer treatment, but it also may benefit the Laboratory’s efforts evaluating antibodies and designing better binding molecules for biosensors that play such a critical role in national security.”

Noy said the technique could be applied to other types of cancer including colon, lung, gastric and pancreatic.

The UC Davis collaborators are one of the leading groups in the radioimmunotherapeutics development field. The group has had promising outcomes from testing this new generation of enhanced radioimmunotherapeutics.

The team’s results open significant new opportunities for researchers in areas ranging from drug design to biophysics.

“We developed a technique that could help to optimize binding affinity, so for this particular application we have looked at super-binders targeting cancer cells,” Noy said. “If the program wants to create a super-binder for a pathogen assay, the technology and the results will be directly applicable.”

In addition to Noy and Sulchek, Livermore scientists Raymond Friddle, Kevin Langry, Edmond Lau, Timothy Ratto and Michael Colvin (who now works at UC Merced) collaborated with UC Davis Cancer Center researchers Huguette Albrecht and Sally DeNardo.

Source: Lawrence Livermore National Laboratory

Related stories:

Scientists identify novel inhibitor of human microRNA
Scientists at The Wistar Institute and their colleagues have identified, for the first time, a molecule that can regulate microRNAs – short strands of RNA that play a vital role in gene expression and are closely associated with cancer. The discovery points the way to the development of a new generation of cancer drugs.
Photonic crystal biosensors detect protein-DNA interactions
Scientists at the University of Illinois have developed a new class of disposable, microplate-based optical biosensors capable of detecting protein-DNA interactions. Based on the properties of photonic crystals, the biosensors are suitable for the rapid identification of inhibitors of protein-nucleic acid and protein-protein interactions.
Researchers discover new drug target for inflammatory disease
UC Davis researchers have defined a cellular process that promotes inflammation and, at the same time, found an important starting point for identifying and testing new drugs for diseases such as sepsis, rheumatoid arthritis, cardiovascular disease and some cancers.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Landmark study opens door to new cancer, aging treatments
Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies.
First step towards switching off breast cancer and leukaemia
Australian scientists have identified a way to 'switch off' a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia.
Structural biology spin-out tackles major diseases
A spin out company from basic structural biology, Asterion Ltd., has led to new technology that provides a way of creating therapeutic proteins to tackle major diseases such as cancer, diabetes and infertility. The research was carried out at the University of Sheffield in laboratories supported by the Biotechnology and Biological Sciences Research Council (BBSRC). This work is reported in the current edition of BBSRC Business, the quarterly research highlights magazine of the Biotechnology and Biological Sciences Research Council.
Researchers unveil vital key to cancer
University of Manchester scientists have uncovered the 3-D structure of Mps1 -- a protein that regulates the number of chromosomes during cell division and thus has an essential role in the prevention of cancer -- which will lead to the design of safer and more effective therapies.

News discussion:

Nanotechnology news